Allarity Therapeutics Inc
allarity.comAllarity Therapeutics Inc (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company developing targeted cancer therapies using a proprietary companion diagnostic platform called DRP (Drug Response Predictor). The company has no commercial revenue as of its 10-K filed 2026-03-30, with operations funded through equity and convertible debt financings rather than product sales. Its lead asset, stenoparib, is a PARP inhibitor licensed from Eisai and is in an ongoing Phase 2 clinical trial for ovarian cancer patients who have received at least three prior lines of therapy. The DRP companion diagnostic is designed to identify patients most likely to respond to treatment, with the FDA having previously approved an Investigational Device Exemption (IDE) for the stenoparib-specific DRP test. Allarity owes Eisai milestone payments of up to $94 million and a $50 million sales milestone if annual stenoparib product sales reach $1 billion, plus royalties on annual incremental sales.
Products & Services
Stenoparib: an oral PARP inhibitor licensed from Eisai, in Phase 2 clinical trials for heavily pre-treated ovarian cancer. DRP (Drug Response Predictor) companion diagnostic platform: a proprietary biomarker tool used to select patients with a DRP score above 50 (DRP+) for enrollment in stenoparib trials. The FDA granted an Investigational Device Exemption (IDE) for the stenoparib-specific DRP diagnostic.
Revenue Model
No product revenue has been generated as of the 10-K filed 2026-03-30. The income statement shows a License Revenue line with no disclosed amounts in the redacted filing. Operations are funded through preferred stock offerings, convertible notes, and private placement financings. The company is pre-commercial and reports net losses for both FY2025 and FY2024.
Customers & Markets
End market is oncology, specifically ovarian cancer patients who have received at least three prior lines of therapy. No commercial customers as of the filing date. Clinical trial sites are located in the U.S. and Europe.
Geographic Exposure
Clinical trial operations span the U.S. and Europe as of the 10-K filed 2026-03-30. The company references potential regulatory submissions to the FDA (U.S.), EMA (Europe), and MHLW (Japan) as future milestones under the Eisai License Agreement.
Financial Snapshot
Loading...
